Breast Cancer
Data reinforce confidence in fulvestrant endocrine therapy for advanced breast cancer
Published in Women's Health Weekly, December 22nd, 2005
Data presented at ECCO 13 may open the door to more women being able to benefit from Faslodex (fulvestrant), an effective treatment for advanced breast cancer after recurrence or progression on hormonal therapy. Results show that fulvestrant is an effective treatment for advanced breast cancer and that women can start to experience the benefits of this therapy within 3 months of commencing treatment.
Conclusive evidence has demonstrated that fulvestrant, which is administered as a once-monthly intra-muscular (IM) injection, is at least as effective as the gold-standard aromatase inhibitor (AI) Arimidex (anastrozole) in this setting, as well as being better tolerated....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer Therapy
Successful lactation is possible after breast-conserving therapy - Cardiology
Diabetes increases risk of in-hospital mortality in women with acute coronary syndrome - Menopause
Hot flashes were linked to anxiety, depression in peri- and post-menopausal women - Rubella Epidemiology
Measles and rubella vaccination efforts are needed among young women in Argentina - Angiography
Breast radiation exposure during pulmonary CT scan exceeds dose for mammography - Apoptosis
Gleditsia sinensis fruit extract induced apoptosis in human carcinoma cells - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
